RxDoctor Payments Data

Nicole Zenon, NP

Family · Austin, TXNPI 1497137731

Payments from drug & device makers

$8,418in general payments, 2019–2025

Across 544 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$757
  • Novo Nordisk$735
  • Amgen$720
  • AstraZeneca$501
  • Boehringer Ingelheim$449
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,418 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$25,345
Medicare patients
147
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$32,789
TrulicityDulaglutide29$27,902
OzempicSemaglutide25$27,648
MounjaroTirzepatide12$12,378
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,783
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,710
Levothyroxine Sodium107$1,147
Atorvastatin Calcium122$1,006
Ventolin HfaAlbuterol Sulfate14$869
Rosuvastatin Calcium71$867
Losartan Potassium80$786
Albuterol Sulfate HfaAlbuterol Sulfate24$701
Duloxetine Hcl32$698
Gabapentin38$645
Potassium Chloride27$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$757$40,28041 claims
Boehringer IngelheimJardiance$449$32,78922 claims
Novo NordiskOzempic$735$27,64825 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,147107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →